Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical

Results with XIENCE V

WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically significant clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System at one year, including continued clinical superiority in major adverse cardiac events (MACE) and continued non- inferior rates of target vessel failure (TVF) with XIENCE V compared to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System. The results were presented at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington D.C.

These results follow the data presented earlier this year at the annual American College of Cardiology conference, wherein XIENCE V demonstrated superiority to TAXUS in the SPIRIT III trial on the study's primary endpoint of in-segment late loss at eight months with a statistically significant 50 percent reduction in late loss compared to TAXUS. (In-segment late loss is a measure of vessel renarrowing).

The SPIRIT III clinical trial of 1,002 patients demonstrated the following key results for XIENCE V at one year:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated clinical superiority to TAXUS with a statistically

significant 43 percent reduction in MACE compared to TAXUS at one year.

These MACE results are consistent with the clinically superior 44

percent reduction in MACE observed for XIENCE V at nine months. MACE is

an important clinical measure of safety and efficacy outcomes for

patients, defined as cardiac death, heart attack (myocardial infarction

or MI), or ischemia-driven target lesion revascularization (TLR driven

by lack of blood supply).

--
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013  The Lupus ... conference devoted to advancing new treatments for lupus nephritis, ... 60 percent of patients. The conference launched a new ... the Lupus Nephritis Trials Network (LNTN). More ... and the kidney came together to focus on two ...
(Date:5/22/2013)... , May 22, 2013 The new ... safe as the previous version used prior to 2010, ... Kaiser Permanente study published today in Vaccine. ... use beginning in 2010 after a series of trials. ... broader range of pneumococcal types than the previously used ...
(Date:5/22/2013)... , May 22, 2013  Healthcare ... enterprise content management (ECM) solution, ... Hospital Information System .  These organizations identified ... system and will use OnBase to optimize ... initiatives.   (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO ...
Breaking Medicine Technology:Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3
... Colorado Cancer,Research Program (CCRP) invites golfers to participate in its ... at the Valley Country Club,14601 Country Club Drive, Aurora. The ... been the home to major events such as the,Colorado Women,s ... professional,golfers have been inducted into the Colorado Hall of Fame., ...
... TAMPA, Fla., April 27 Calvin A. ... from his 60-patient,retrospective case control study that ... Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R),(ranibizumab) ... degeneration (AMD) in an oral poster presentation ...
Cached Medicine Technology:Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 2Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... more likely to attempt suicide, whether or not they ... to a new study. "Clinicians who are seeing ... are at increased risk of suicide," said study co-author ... Treatment Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Rapids, IA (PRWEB) May 22, 2013 ... theatre piece Handicap This! The performance promotes awareness ... their dreams. The Handicap This! performance will be held ... Mar High School auditorium. Tickets for Handicap This! ... Handicap This! helps audiences measure the level to which ...
(Date:5/22/2013)... SAN FRANCISCO Researchers in genomic health disparities from ... the Stanford University School of Medicine have teamed up ... Conference to Eliminate Health Disparities in Genomic Medicine." ... role of nonprofits, business and government to reduce these ... of the United States, individuals within underserved groups continue ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... has established the Westchester Lung Nodule Center for ... or receive lung cancer care. Lung cancer is the deadliest ... year, more people in the U.S. die from lung cancer ... As with all cancers, early detection increases survival rates. ...
Breaking Medicine News(10 mins):Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3
... eCare, an initiative that employs information,and advanced technologies ... care, WILLIAMSBURG, Va., June 18 The ... and Mary proudly announces that,Professor Dorothea La "Chon" ... awards available to a faculty member in a ...
... source; New York City links 7 infections to salmonella ... number of people known to have fallen ill after ... 30 states plus the District of Columbia, U.S. health ... not due to new infections but mainly because some ...
... Corporation,(Nasdaq: AIRM ), the largest air medical ... Executive Officer Aaron Todd and Chief,Financial Officer Trent ... Conference in New York City on Tuesday, June ... can listen to the presentation via a live ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... seizures, SPOKANE, Wash., June 18 The Epilepsy,Foundation ... this Saturday, June 21 in Spokane at Riverfront Park ... from 9:30 am - 12:30 pm., "Everyone is ... with epilepsy," said Ryan Oelrich, Program Manager. "We are ...
... Berkeley The newly sequenced genome of a dainty, quill-like ... that vertebrates evolved over the past 550 million years through ... ,The late geneticist Susumu Ohno argued in 1970 ... evolution of higher organisms, and Ohno,s theory was the basis ...
Cached Medicine News:Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 2Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 3Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 4Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 5Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 2Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 3Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: